Clinical Trial Comparing Transurethral Microwave Thermotherapy and Prostatic Artery Embolisation for Reducing Severe Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia

What this Trial Is About

This clinical trial compares two minimally invasive treatments, transurethral microwave thermotherapy (TUMT) and prostatic artery embolisation (PAE), for men with severe lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). The study aims to determine if TUMT is not worse than PAE in reducing urinary symptoms six months after treatment, using the International Prostate Symptom Score (IPSS) as the main measure. Both treatments aim to shrink the prostate and relieve symptoms, but their effectiveness has not been directly compared in a randomized clinical trial before. Participants will be randomly assigned to receive either TUMT or PAE. In TUMT, a device that emits microwave energy is inserted through the urethra to heat and reduce prostate tissue, with temperature monitored to ensure safety. PAE involves inserting a catheter into the arteries supplying the prostate to block blood flow, causing the prostate to shrink. Both procedures are done in outpatient settings and aim to improve symptoms by reducing prostate size. During the study, participants will be monitored at multiple points up to five years after treatment to assess urinary symptoms, quality of life, satisfaction, side effects, and the need for additional treatments. Evaluations include patient surveys, urine flow measurements, prostate volume checks, and laboratory tests. The main outcome will be the average symptom score six months post-procedure, with additional follow-ups to understand long-term effects and help guide treatment choices.

Clinical Trial on the Effectiveness of TUMT Compared to PAE in Reducing Severe LUTS in Men with BPH